{
    "nctId": "NCT06495541",
    "briefTitle": "The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive",
    "officialTitle": "The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, RWS, Pyrotinib",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 18 years old;\n2. Pathological or histopathological confirmed HER2 positive cases cannot be surgically advanced or metastasized Patients with sexual breast cancer (HER2 positive is defined as: standard immunohistochemistry (IHC) Detected as 3+or ISH positive);\n3. There is a traceable medical history record during the treatment period;\n4. Voluntarily participate in this study, sign informed consent, have good compliance, and are willing to cooperate Follow up.\n\nExclusion Criteria:\n\n1. Failure to sign informed consent form;\n2. Previous history of other malignant tumors, but cured skin basal cell carcinoma and cervical cancer Excluding cancer;\n3. Difficulty in swallowing, chronic diarrhea, and intestinal obstruction, which can affect medication administration and absorption Various factors;\n4. Pregnant or lactating women, and women of childbearing age who cannot achieve optimal contraception;\n5. Any other circumstances in which the researcher deems the patient unsuitable to participate in this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}